Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Sectra leads the market in PACS considerations and selections

LINKÖPING, Sweden and SHELTON, Conn., Dec. 7, 2023 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is the most widely considered vendor in the US according to the PACS 2023 Decision Insights Report from KLAS Research. Sectra is included in half of the purchase decisions and selected in 25% of these significantly more than any other vendor in the report.

Reasons attributed to Sectra's success include its favorable peer recommendations fostered by robust customer relationships and innovative, user-friendly technology. Its strong integration capabilities with EHRs and other solutions are an additional contributing factor to the company's strong market energy. 

"It is important to recognize that even though Sectra has considerable opportunities with new healthcare providers, 98% of our existing surveyed customers said Sectra was part of their long-term plans. This reinforces our belief that excellent products and happy customers will drive future business," says Isaac Zaworski, President of Sectra Inc.

KLAS Research has been providing accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996. Their mission is to improve the world's healthcare through insights, collaboration, and transparency. To read the full report, visit https://klasresearch.com/report/pacs-2023-decision-insights/3386

About Sectra

With 30 years of innovation and more than 2,000 installations around the globe, Sectra is a leading imaging IT provider to health systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA. Over the last ten consecutive years, Sectra has been awarded Best in KLAS for highest customer satisfaction. For more information, visit Sectra's website.

For further information, please contact: 
Dr. Torbjörn Kronander, CEO and President Sectra  AB, 46 (0) 705 23 52 27
Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10

The following files are available for download:


Sectra's radiology solution


These press releases may also interest you

at 18:59
FINN Partners, a global independent marketing and communications agency, and Humble Ventures, a venture capital and private equity firm focused on diverse founders, entrepreneurs, start-ups and organizations, are joining forces for the second year in...

at 18:15
The "Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), and End User (Hospital, Imaging Center, Pharmaceutical) -...

at 18:00
Pacific Cataract and Laser Institute, Inc., P.C. ("Pacific Cataract and Laser") is providing notice of a recent data privacy event that may have affected the personal and protected health information related to certain individuals. At this time,...

at 18:00
The "Pharmaceutical Quality Management Systems Market by Solution Type (Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change, Training Management), Deployment Mode (Cloud, On-premise), and End User (Pharmaceutical, CDMO/CRO) -...

at 17:25
Spyre Therapeutics, Inc. (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel...

at 17:21
Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial. The company is pleased to announce Dr....

News published on and distributed by: